The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation
Open accessAbstract
BACKGROUND: Testing of factor Xa inhibitors for the prevention of cardiovascular events in patients with rheumatic heart disease-associated atrial fibrillation has been limited. METHODS: , left atrial spontaneous echo contrast, or left atrial thrombus. Patients were randomly assigned to receive standard doses of rivaroxaban or dose-adjusted vitamin K antagonist. The primary efficacy outcome was a composite of stroke, systemic embolism, myocardial infarction, or death from vascular (cardiac or noncardiac) or unknown causes. We hypothesized that rivaroxaban therapy would be noninferior to vitamin K antagonist therapy. The primary safety outcome was major bleeding according to the International Society of Thrombosis and Hemostasis. RESULTS: Of 4565 enrolled patients, 4531 were included in the final analysis. The mean age of the patients was 50.5 years, and 72.3% were women. Permanent discontinuation of trial medication was more common with rivaroxaban than with vitamin K antagonist therapy at all visits. In the intention-to-treat analysis, 560 patients in the rivaroxaban group and 446 in the vitamin K antagonist group had a primary-outcome event. Survival curves were nonproportional. The restricted mean survival time was 1599 days in the rivaroxaban group and 1675 days in the vitamin K antagonist group (difference, -76 days; 95% confidence interval [CI], -121 to -31; P<0.001). A higher incidence of death occurred in the rivaroxaban group than in the vitamin K antagonist group (restricted mean survival time, 1608 days vs. 1680 days; difference, -72 days; 95% CI, -117 to -28). No significant between-group difference in the rate of major bleeding was noted. CONCLUSIONS: Among patients with rheumatic heart disease-associated atrial fibrillation, vitamin K antagonist therapy led to a lower rate of a composite of cardiovascular events or death than rivaroxaban therapy, without a higher rate of bleeding. (Funded by Bayer; INVICTUS ClinicalTrials.gov number, NCT02832544.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ruff, C. T., Giugliano, R. P., Braunwald, E., Hoffman, E. B., Deenadayalu, N., Ezekowitz, M. D., Camm, A. J., Weitz, J. I., Lewis, B. S., Parkhomenko, A., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62343-0 · Cited by 5,051
Hart, R. G., Pearce, L. A., & Aguilar, M. I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00007 · Cited by 4,793
Rivaroxaban with or without aspirin in stable cardiovascular disease
Eikelboom, J. W., Connolly, S. J., Bosch, J., Dagenais, G. R., Hart, R. G., Shestakovska, O., Diaz, R., Alings, M., Lonn, E. M., Anand, S. S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709118 · Cited by 2,438
Self-citationJanuary, C. T., Wann, L. S., Calkins, H., Chen, L. Y., Cigarroa, J. E., Cleveland, J. C., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., Furie, K. L., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.01.011 · Cited by 2,205
Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm
Homma, S., Thompson, J. L. P., Pullicino, P. M., Levin, B., Freudenberger, R. S., Teerlink, J. R., Ammon, S. E., Graham, S., Sacco, R. L., Mann, D. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202299 · Cited by 584
Pan, K., Singer, D. E., Ovbiagele, B., Wu, Y., Ahmed, M., & Lee, M. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.005835 · Cited by 167
The ACTIVE Steering Committee (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.06.026 · Cited by 105
Atrial fibrillation in Sub-Saharan Africa: epidemiology, unmet needs, and treatment options
Stambler, B. S., & Ngunga, L. M. (2015) · International Journal of General Medicine · doi:10.2147/ijgm.s84537 · Cited by 79
Management of atrial fibrillation in patients with rheumatic mitral stenosis
Iung, B., Leenhardt, A., & Extramiana, F. (2018) · Heart · doi:10.1136/heartjnl-2017-311425 · Cited by 73
Cited by
Van Gelder, I. C., Rienstra, M., Bunting, K. V., Casado-Arroyo, R., Caso, V., Crijns, H. J. G. M., De Potter, T. J. R., Dwight, J., Guasti, L., Hanke, T., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae176 · Cited by 3,024
Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., Deswal, A., Eckhardt, L. L., Goldberger, Z. D., Gopinathannair, R., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001193 · Cited by 2,765
2025 ESC/EACTS Guidelines for the management of valvular heart disease
Praz, F., Borger, M. A., Lanz, J., Marin-Cuartas, M., Abreu, A., Adamo, M., Ajmone Marsan, N., Barili, F., Bonaros, N., Cosyns, B., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf194 · Cited by 1,072
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation
Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., Deswal, A., Eckhardt, L. L., Goldberger, Z. D., Gopinathannair, R., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.08.017 · Cited by 933
Kumbhani, D. J., Armbruster, A. L., Cheng, R. K., Chrispin, J., Fischer, U., Holbrook, A. M., Joglar, J., & Sevestre, M.-A. (2026) · JACC · doi:10.1016/j.jacc.2026.05.033 · Cited by 2
Metadata
- Authors
- Connolly, S. J., Karthikeyan, G., Ntsekhe, M., Haileamlak, A., El Sayed, A., El Ghamrawy, A., Damasceno, A., Avezum, A., Dans, A. M. L., Gitura, B., Hu, D., Kamanzi, E. R., Maklady, F., Fana, G., Gonzalez-Hermosillo, J. A., Musuku, J., Kazmi, K., Zühlke, L., Gondwe, L., Ma, C., Paniagua, M., Ogah, O. S., Molefe-Baikai, O. J., Lwabi, P., Chillo, P., Sharma, S. K., Cabral, T. T. J., Tarhuni, W. M., Benz, A., van Eikels, M., Krol, A., Pattath, D., Balasubramanian, K., Rangarajan, S., Ramasundarahettige, C., Mayosi, B., & Yusuf, S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-09-15
- Volume
- 387
- Issue
- 11
- Pages
- 978-988
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4293410833
- Cited by
- 267
- References
- 11
- FWCI
- 34.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation. https://app.cochat.ai/papers/10.1056/nejmoa2209051
- The paper
- Connolly, S. J., Karthikeyan, G., Ntsekhe, M., Haileamlak, A., El Sayed, A., El Ghamrawy, A., Damasceno, A., Avezum, A., Dans, A. M. L., Gitura, B., Hu, D., Kamanzi, E. R., Maklady, F., Fana, G., Gonzalez-Hermosillo, J. A., Musuku, J., Kazmi, K., Zühlke, L., Gondwe, L., . . . Yusuf, S. (2022). Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2209051
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.